VERO Stock - Venus Concept Inc.
Unlock GoAI Insights for VERO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $64.83M | $76.35M | $99.50M | $105.62M | $78.01M |
| Gross Profit | $44.31M | $52.17M | $65.97M | $74.09M | $51.39M |
| Gross Margin | 68.3% | 68.3% | 66.3% | 70.2% | 65.9% |
| Operating Income | $-27,184,000 | $-28,309,000 | $-34,876,000 | $-14,767,000 | $-67,898,000 |
| Net Income | $-46,996,000 | $-37,250,000 | $-43,700,000 | $-23,013,000 | $-81,706,000 |
| Net Margin | -72.5% | -48.8% | -43.9% | -21.8% | -104.7% |
| EPS | $-66.28 | $-6.84 | $-9.91 | $-6.34 | $-33.92 |
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
VEROEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-3.61 | $-12.14 | -236.3% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-9.72 | $-8.03 | +17.4% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-14.08 | $-17.44 | -23.9% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-10.01 | $-11.23 | -12.2% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.20 | $-14.08 | -1073.3% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.43 | $-15.29 | -969.2% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-1.53 | $-18.48 | -1107.8% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-1.18 | $-22.11 | -1773.7% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-1.51 | $-18.04 | -1094.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.54 | $-14.85 | -864.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-2.12 | $-20.35 | -859.9% | ✗ MISS |
Q1 2023 | Mar 27, 2023 | $-0.14 | $-23.09 | -16392.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-19.79 | $-36.29 | -83.4% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-13.19 | $-26.39 | -100.1% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-16.49 | $-21.44 | -30.0% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-19.79 | $-13.19 | +33.4% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-21.44 | $-29.69 | -38.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-23.09 | $-6.60 | +71.4% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-24.74 | $-28.04 | -13.3% | ✗ MISS |
Latest News
Venus Concept shares are trading lower after the company reported worse-than-expected Q3 sales results.
📉 NegativeVenus Concept Q3 EPS $(12.14) Sales $13.776M Miss $14.482M Estimate
📉 NegativeVenus Concept shares are trading higher after the company received FDA 510(k) clearance for its Venus NOVA non-invasive body and skin treatment device.
📈 PositiveVenus Concept Receives 510(k) For Venus NOVA Non-Invasive Body and Skin Treatments
📈 PositiveVenus Concept Exchanged The Full $11.48M Balance Of Its Subordinated Convertible Notes Held By Affiliates Of Madryn Asset Management For 545,335 Shares Of Its Series Y Preferred Stock; Co Had Total Debt Obligations Of ~$30.1M, A Reduction Of 24% Compared To $39.7M Outstanding As Of December 31, 2024
📈 PositiveVenus Concept Has Received A Decision To Grant European Patent Number EP3542745 Titled "DEVICE FOR FRACTIONAL RF TREATMENT OF THE SKIN (TO IMPROVE APPEARANCE)".
📈 PositiveVenus Concept Sells Venus Hair Unit
➖ NeutralVenus Concept prices $3.45M in direct offering, warrants; shares up over 29%
📈 PositiveVenus Concept to sell Venus Hair business for $20M, stock soars 50%
📈 PositiveFrequently Asked Questions about VERO
What is VERO's current stock price?
What is the analyst price target for VERO?
What sector is Venus Concept Inc. in?
What is VERO's market cap?
Does VERO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VERO for comparison